Isis Pharmaceuticals Inc. (ISIS) announced after the close Wednesday that data from the Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy were presented at the 65th American Academy of Neurology Annual Meeting.
Isis Pharmaceuticals has been rising since the open of trade Thursday and is now up 1.60 at $19.44 on above average volume. The stock has climbed above a 2-week range and has set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.